Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

High Dose Rate Prostate (HDR) Brachytherapy Dose Escalation to Dominant Intra-prostatic Nodule for Patients With Intermediate and High Risk Prostate Cancer

NCT01605097 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT01605097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01605097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
High Dose Rate Prostate (HDR) Brachytherapy Dose Escalation to Dominant Intra-prostatic Nodule for Patients With Intermediate and High Risk Prostate Cancer
Lead sponsor
British Columbia Cancer Agency
Phase
Not applicable
Overall status
Completed
Start date
May 31, 2012
Completion date
July 31, 2018
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer